Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report)'s stock had its "hold" rating reiterated by investment analysts at Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports.
Lexicon Pharmaceuticals Stock Performance
Shares of NASDAQ LXRX traded up $0.01 during trading hours on Thursday, reaching $2.03. 1,749,626 shares of the stock were exchanged, compared to its average volume of 4,527,476. The firm has a market capitalization of $499.87 million, a price-to-earnings ratio of -2.52 and a beta of 1.27. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60. Lexicon Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $3.79. The stock's fifty day simple moving average is $2.42 and its 200 day simple moving average is $1.67.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. Sell-side analysts predict that Lexicon Pharmaceuticals will post -0.71 EPS for the current year.
Institutional Investors Weigh In On Lexicon Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in LXRX. Swiss National Bank grew its position in Lexicon Pharmaceuticals by 10.6% during the first quarter. Swiss National Bank now owns 140,800 shares of the biopharmaceutical company's stock worth $294,000 after buying an additional 13,500 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Lexicon Pharmaceuticals in the 1st quarter valued at $26,000. Dimensional Fund Advisors LP boosted its holdings in shares of Lexicon Pharmaceuticals by 12.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 869,611 shares of the biopharmaceutical company's stock valued at $1,818,000 after purchasing an additional 96,633 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Lexicon Pharmaceuticals by 2.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 501,128 shares of the biopharmaceutical company's stock valued at $1,048,000 after purchasing an additional 12,710 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the 1st quarter valued at $186,000. Institutional investors and hedge funds own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
See Also
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
